Skip to content

Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus

Prospective Pilot Cohort Study to Assess Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03388047
Acronym
MuSE
Enrollment
20
Registered
2018-01-02
Start date
2018-01-01
Completion date
2020-12-31
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Barrett Esophagus, Esophageal Neoplasms, Reflux Esophagitis

Keywords

Barrett Esophagus, Endoscopy, Adenocarcinoma

Brief summary

Multispectral imaging represents an exciting new field of investigation in endoscopic research. Multispectral imaging uses a specialised camera to detect multiple colours, allowing us to build a rough spectrum from each point in our image. It is widely reported that these spectra are different for different tissue types, but this is difficult to study ex vivo since de-oxygenation of the blood and decay of the tissue change these spectra considerably. The investigators have therefore designed this study to asses the different multispectral imaging spectra of Barrett's Oesophagus, which we believe might be utilised as a method to detect dysplasia in the future.

Detailed description

The investigators have developed a custom multispectral endoscopes based around a CE marked device, the PolyScope disposable endoscope (PolyDiagnost). This is a combined sterile catheter and fibre optic device designed to optimize light delivery to the anatomy and to acquire and transmit endoscopic images back to a camera. This CE marked system can be used to endoscope luminal organs such as the oesophagus, but also biliary tract, the bladder and the oro-pharynx. The PolyScope can be inserted thought the accessory channel of commercial endoscopes. The design of the fibre optic device is durable and re-useable; it is inserted within the disposable sterile catheter channel, which is able to flex and bend to orient the device to the region of interest for imaging. The fibre optic device never comes into contact with the patient. The sterile catheter, which shields the fibre optic device, is disposed following a procedure. The use of the PolyScope provides the advantage of building on a known system. The commercial PolyScope probe is coupled outside of the patient to a custom multispectral detection and illumination system. No modified part of the device comes into contact with the patient. The patients recruited to this study will have a clinical indication to an endoscopic examination for Barrett's oesophagus or early oesophageal adenocarcinoma. There will not be extra procedures involved. The experimental part of the procedure, using Polyscope multispectral endoscope will prolong the procedure in most cases by approximately 5-10 minutes

Interventions

DEVICEEndoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source

During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions

Sponsors

University of Cambridge
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female subjects over 18 years * Previous diagnosis of Barrett's oesophagus, with an endoscopic length of at least 2 cm * Previous diagnosis of oesophageal glandular dysplasia or early oesophageal adenocarcinoma for consideration of endoscopic therapy

Exclusion criteria

* History of oesophageal stricture precluding passage of the endoscope, * Pregnancy, or planned pregnancy during the course of the study, * Currently breastfeeding * Any history of esophageal varices, liver impairment of moderate or worse severity (Child's- Pugh class B & C) or evidence of varices on initial treatment endoscopy, * Any history of oesophageal surgery, except for uncomplicated fundoplication, and, * History of coagulopathy, with INR\>1.3 and/or platelet count of \<75,000. * On clopidogrel, and/or warfarin for high risk condition and unable to withhold temporarily the medication.

Design outcomes

Primary

MeasureTime frameDescription
Level of confidence in delineating the area of interest by multispectral imaging1 yearLevel of confidence in delineating the area of interest by the multispectral endoscope in terms of image quality and visibility of area of interest assessed by endoscopist using a 1 to 10 Visual Analogue Score (VAS). We will consider the following ranges 0-3 poor; 4-5 fair; 6-8 good, 9-10 excellent

Secondary

MeasureTime frameDescription
Imaging spectra by multispectral endoscopy in neoplastic vs. non-neoplastic Barrett's1 yearNumber and type of image spectra corresponding to neoplastic and non-neoplastic area of Barrett's Oesophagus
Patient comfort1 yearPatient comfort score measured by assisting nurse according to standard scoring scale (1 to 5)
Time1 yearTime to perform multispectral imaging in minutes
Correlation with molecular biomarkers1 yearComparison of the biomarker features of biopsies directed by multispectral imaging (both neoplastic and non-neoplastic) using a molecular panel assessing aneuploidy, p53 and cyclin A.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026